Jules A. A. C. Heuberger

University of Applied Sciences Leiden — Netherlands

Medicine · Health Sciences

20h-index1.4kcitations61works5.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Hormonal and reproductive studies(9), Erythropoietin and Anemia Treatment(9), Cannabis and Cannabinoid Research(8), Doping in Sports(7), Ion channel regulation and function(6)

Publications61 total

Low‐dose cannabidiol increases plasma concentrations of amitriptyline: A clinical drug–drug interaction study
British Journal of Clinical Pharmacology·2025Open Access
Cannabidiol Lacks Direct Effect on Cortical Excitability: A Randomized, Double Blind, Placebo Controlled, 3‐Way Crossover Trial
Clinical Pharmacology & Therapeutics·2025Open Access
Investigational eIF2B activator DNL343 modulates the integrated stress response in preclinical models of TDP-43 pathology and individuals with ALS in a randomized clinical trial
Nature Communications·2025· 4 citedOpen Access
Sentinel dosing: A proposed algorithm to guide decision making on which cohorts in early phase clinical pharmacology trials should use this approach
British Journal of Clinical Pharmacology·2025· 2 citedOpen Access
<scp>CB<sub>1</sub></scp> Receptor Antagonist Selonabant (<scp>ANEB</scp>‐001) Blocks Acute <scp>THC</scp> Effects in Healthy Volunteers: A Phase II Randomized Controlled Trial
Clinical Pharmacology & Therapeutics·2025· 2 citedOpen Access
Safety, Pharmacokinetics, and Pharmacodynamics of a First‐in‐Class <scp>ClC</scp>‐1 Inhibitor to Enhance Muscle Excitability: Phase I Randomized Controlled Trial
Clinical Pharmacology & Therapeutics·2024· 3 citedOpen Access
<scp>TMS</scp> and <scp>EEG</scp> Pharmacodynamic Effects of a Selective Sphingosine‐1‐Phosphate Subtype 1 Receptor Agonist on Cortical Excitability in Healthy Subjects
Clinical Pharmacology & Therapeutics·2024· 2 citedOpen Access
Cannabidiol Increases Psychotropic Effects and Plasma Concentrations of Δ<sup>9</sup>‐Tetrahydrocannabinol Without Improving Its Analgesic Properties
Clinical Pharmacology & Therapeutics·2024· 15 citedOpen Access
The ClC-1 chloride channel inhibitor NMD670 improves skeletal muscle function in rat models and patients with myasthenia gravis
Science Translational Medicine·2024· 24 cited
SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF A CLC-1 INHIBITOR - A FIRST-IN-CLASS COMPOUND THAT ENHANCES MUSCLE EXCITABILITY: A PHASE I, SINGLE- AND MULTIPLE-ASCENDING DOSE STUDY
2024· 1 citedOpen Access
P272 NMD670, a novel first-in-class muscle ClC-1 inhibitor, improves symptoms of myasthenia gravis: a randomized, single-dose, double-blind, placebo-controlled study
Neuromuscular Disorders·2023· 1 cited
304 Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
Annals of Emergency Medicine·2023· 5 citedOpen Access
380 Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 for Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic/Pharmacodynamic Model
Annals of Emergency Medicine·2023Open Access
Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations
British Journal of Clinical Pharmacology·2023· 1 citedOpen Access
N°356 - Muscle velocity recovery cycles as pharmacodynamic biomarker in a first-in-human trial of a first-in-class chloride channel 1 inhibitor: A randomized, double-blind, placebo-controlled, cross-over study in healthy subjects and patients with myasthenia grav
Clinical Neurophysiology·2023
A <scp>leucine‐rich</scp> repeat kinase 2 (<scp>LRRK2</scp>) pathway biomarker characterization study in patients with Parkinson's disease with and without <scp>LRRK2</scp> mutations and healthy controls
Clinical and Translational Science·2023· 12 citedOpen Access
The Integrated Stress Response Is Modulated by eIF2B Agonist DNL343: Results From Phase 1 Healthy Subject and Phase 1b ALS Patient Studies. (P8-8.010)
Neurology·2023· 10 cited
<scp>LRRK2</scp> Inhibition by <scp>BIIB122</scp> in Healthy Participants and Patients with Parkinson's Disease
Movement Disorders·2023· 99 citedOpen Access
Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study
Clinical and Translational Science·2022· 6 citedOpen Access
TH-186. Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized, double-blind, placebo-controlled, cross-over study in healthy subjects
Clinical Neurophysiology·2022
page 1 of 4Next →

Frequent Co-authors

Geert Jan Groeneveld(25), Adam F. Cohen(15), Marieke L. de Kam(8), Titia Q. Ruijs(7), Maurits F. J. M. Vissers(6), Joop van Gerven(6), Jacobus Burggraaf(6), Pim Gal(6), Frederik E. Stuurman(6), Kimberly Scearce‐Levie(5), Carole Ho(5), Matthew D. Troyer(5), Erica S. Klaassen(5), Linda E. Klumpers(5), Joris I. Rotmans(5), Johannes M. A. Daniels(5), Annika A. de Goede(5), Fen Huang(4), Catherine M.K.E. de Cuba(4), Eva R. Chin(4)